Merck
  • 主页
  • 查找结果
  • Mycophenolate mofetil ameliorates diabetic nephropathy through epithelial mesenchymal transition in rats.

Mycophenolate mofetil ameliorates diabetic nephropathy through epithelial mesenchymal transition in rats.

Molecular medicine reports (2015-06-18)
Xiaoyan Xiao, Jie Wang, Xiangdi Chang, Junhui Zhen, Gengyin Zhou, Zhao Hu
摘要

Recent studies in animal models have revealed that mycophenolate mofetil (MMF) has certain protective effects against experimental diabetic nephropathy. The present study therefore aimed to investigate the hypothesis that diabetic nephropathy may be ameliorated by mycophenolate mofetil and benazepril treatment alone or in combination, and identify the potential underlying mechanisms in a rat model. Diabetes was induced in rats by a single intraperitoneal injection of streptozotocin. Rats were subsequently treated with benazepril, MMF or a combination of the two drugs, and blood glucose, normalized kidney weight, urine protein and serum creatinine were determined. The pathological changes in renal tissue were also observed. In addition, indices of epithelial mesenchymal transition, including α‑smooth muscle actin (α‑SMA) and transforming growth factor (TGF)‑β1 expression, were examined. Normalized kidney weight, urine protein and serum creatinine levels were significantly improved in the diabetic rats treated with benazepril or mycophenolate mofetil, compared with those of rats in the untreated diabetic group. Pathological changes in the kidney were detected concurrently with increasing kidney weight and urinary albumin excretion, with a similar trend in variation among groups. In addition, the expression of epithelial mesenchymal transition indices, including α‑SMA and TGF‑β1, in the renal tubule interstitium were significantly decreased in the benazepril‑ and MMF‑treated groups compared with those of the diabetic group. As expected, the aforementioned indices were markedly lower in the benazepril and MMF combined treatment group than those in the single medication groups. These data suggested that MMF may have a protective role in diabetic nephropathy, and that the underlying mechanism may be partially dependent upon the suppression of the epithelial mesenchymal transition. Furthermore, the combination of benazepril and MMF conferred enhanced efficacy over monotherapies in the treatment of diabetic nephropathy.

材料
货号
品牌
产品描述

Sigma-Aldrich
纯乙醇, 200 proof, anhydrous, ≥99.5%
Sigma-Aldrich
甲醛 溶液, ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)
Sigma-Aldrich
链脲菌素, ≥75% α-anomer basis, ≥98% (HPLC), powder
Sigma-Aldrich
甲醛 溶液, for molecular biology, 36.5-38% in H2O
Sigma-Aldrich
纯乙醇, 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
纯乙醇, 190 proof, meets USP testing specifications
Sigma-Aldrich
甲醛 溶液, for molecular biology, BioReagent, ≥36.0% in H2O (T)
Sigma-Aldrich
肌酸酐, anhydrous, ≥98%
Sigma-Aldrich
甲醛 溶液, meets analytical specification of USP, ≥34.5 wt. %
Sigma-Aldrich
双酚A型环氧树脂, used as embedding medium
Supelco
10% (v/v) 乙醇标准品, 10 % (v/v) in H2O, analytical standard
Sigma-Aldrich
80% v/v 乙醇固定液, suitable for fixing solution (blood films)
Sigma-Aldrich
纯乙醇, 200 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
Sigma-Aldrich
纯乙醇, 190 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
Sigma-Aldrich
纯乙醇, 160 proof, Excise Tax-free, Permit for use required
Sigma-Aldrich
甲醛-12C 溶液, 20% in H2O, 99.9 atom % 12C